Simple Summary The myeloproliferative neoplasms (MPNs) are chronic blood cancers characterized by elevated blood cell counts and, after decades, the development of bone marrow failure. Blood clots are common and contribute massively to the symptom burden. Treatment with interferon (IFN) alpha-2 normalizes elevated blood cell counts within weeks to months. This treatment has been used […]
Real-World Treatments and Thrombotic Events in U.S. based Polycythemia Vera Patients
Abstract Polycythemia vera (PV) is a myeloproliferative neoplasm associated with increased risk of thrombotic events (TE) and death. Therapeutic interventions, phlebotomy and cytoreductive medications, are targeted to maintain hematocrit levels < 45% to prevent adverse outcomes. This retrospective observational study examined medical and pharmacy claims of 28,306 PV patients initiating treatment for PV in a data period […]
PharmaEssentia Announces New Research and Development Center in Boston
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation January 4, 2023 8:00 AM EST TAIPEI,Taiwan–(BUSINESS WIRE)–PharmaEssentia Corporation, (TPEx:6446), a global biopharmaceutical innovator headquartered in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced […]
Is there a Connection between MPNs and Autoimmune Diseases?
by David Wallace Patients are Asking – Episode 2 of 3 In this interview with MPN expert, Dr. Angela Fleischman, we discuss the latest treatments for myelofibrosis (MF) and when a clinical trial should be considered. Research has linked MPNs to a pre-disposition to autoimmune disorders such as Lupus, Crohn’s disease and Psoriasis just to […]
Access to comprehensive support is a “must have” in managing PV
Sponsored Post An interview with Christina Liston, Director of Patient Access at PharmaEssentia It’s no secret in the polycythemia vera (PV) community that the patient journey comes with many challenges, sometimes feeling like a roller coaster ride. It impacts us at a physical, mental, and spiritual level. For many people, the disease comes with a […]
MPN Patient Advocacy Works!
by David Wallace I got my first shot of Pegasys 3 days ago, along with my local doctor’s agreement to monitor my counts. It was not without a HARD push on my part, as Doc was still pushing the benefits of HU (hydroxyurea), while reinforcing the numerous risks with Peg. For once, I was glad […]
Pregnancy and Childbirth Outcomes in Women with MPNs
A Nationwide population-based study of 342 pregnancies in Sweden Abstract Pregnancy and childbirth in women with myeloproliferative neoplasms (MPN) are reported to be associated with maternal thrombosis, hemorrhage, and placental dysfunction. To assess the risks of adverse events in pregnancy in women with MPN, we performed a large population-based study using Swedish health care registers, […]
MPN Awareness Day!
by David Wallace Today we celebrate MPN Awareness Day with our community! We are focused 24/7 on providing valuable resources to patients, caregivers and healthcare providers via our websites PV Reporter and MPN Cancer Connection. MPN Awareness and education is a daily practice rather than a special event. —> For myself personally, I take great […]
Paving the way to improve therapy for MPNs
Megan Bywater & Steven W. Lane, Nature Communications volume 13, Article number: 5025, Published: August 26, 2022 Long-acting IFNα induces durable molecular responses in myeloproliferative neoplasms. Emerging studies, including Saleiro et al. recently published in Nature Communications, have identified promising candidates that may synergize with IFNα by targeting stem cell function or feedback loops that mediate […]
Treatments for ET and PV Moving Towards Disease Modification
by Christina T. Loguidice, OncLive Prevention and mitigation of cardiovascular events, such as thrombohemorrhagic complications, have been the main goal of treatment development for patients with essential thrombocythemia and polycythemia vera. Prevention and mitigation of cardiovascular events, such as thrombohemorrhagic complications, have been the main goal of treatment development for patients with essential thrombocythemia (ET) […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 21
- Next Page »
